An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy

Trial Profile

An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Jul 2015

At a glance

  • Drugs Carotuximab (Primary) ; Axitinib; Bevacizumab; Capecitabine; Pazopanib
  • Indications Advanced breast cancer; Fallopian tube cancer; Glioblastoma; Gliosarcoma; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Therapeutic Use
  • Sponsors TRACON Pharmaceuticals
  • Most Recent Events

    • 05 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top